Expensive care — a rationale for economic evaluations in intensive care

Critical Care and Resuscitation

Volumn 12, Issue 1, 2010, Pages 62-66

  Higgins, Alisa M ^a   Pettila, Ville ^a   Bellomo, Rinaldo ^a,b,c   Harris, Anthony H ^a   Nichol, Alistair D ^a   Morrison, Siouxzy S ^a  

^a MONASH UNIVERSITY   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c AUSTIN HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AUSTRALIA; COST BENEFIT ANALYSIS; ECONOMICS; HEALTH CARE COST; HEALTH CARE POLICY; HUMAN; INTENSIVE CARE; QUALITY ADJUSTED LIFE YEAR; REVIEW; STATISTICS;

AUSTRALIA; COST-BENEFIT ANALYSIS; HEALTH CARE COSTS; HEALTH POLICY; HUMANS; INTENSIVE CARE; QUALITY-ADJUSTED LIFE YEARS;

EID: 77952780346     PISSN: 14412772     EISSN: 26529335     Source Type: Journal    
DOI: 10.1016/S1441-2772(23)01360-1     Document Type: Review

References (34)

1. Halpern, N.A., Pastores, S.M., Greenstein, R.J., Critical care medicine in the United States 1985-2000: an analysis of bed numbers, use, and costs. Crit Care Med 32 (2004), 1254–1259.
2. Talmor, D., Shapiro, N., Greenberg, D., et al. When is critical care medicine cost-effective? A systematic review of the cost-effectiveness literature. Crit Care Med 34 (2006), 2738–2747.
3. Chalfin, D.B., Cohen, I.L., Lambrinos, J., The economics and cost-effectiveness of critical care medicine. Intensive Care Med 21 (1995), 952–961.
4. Harwood, R.H., Economic evaluations of complex services for older people. Age Ageing 37 (2008), 491–493.
5. Halton, K.A., Cook, D.A., Whitby, M., et al. Cost effectiveness of antimicrobial catheters in the intensive care unit: addressing uncertainty in the decision. Crit Care, 13, 2009, R35.
6. Tilden, D.P., Chapman, J., Davey, P.J., et al. A decision-analytic economic evaluation of valaciclovir prophylaxis for the prevention of cytomegalovirus infection and disease in renal transplantation. Clin Transplant 18 (2004), 312–320.
7. Economic outcome for intensive care of infants of birthweight 500-999 g born in Victoria in the post surfactant era. The Victorian Infant Collaborative Study Group. J Paediatr Child Health, 33, 1997, 202–208.
8. Segal, L., Mortimer, D., Dalziel, K., Executive report. Risk factor study: how to reduce the burden of harm from poor nutrition, tobacco smoking, physical inactivity and alcohol misuse: cost-utility analysis of 29 interventions. 2005, Centre for Health Economics, Monash University, Melbourne.
9. Carter, R., Marks, R., Hill, D., Could a national skin cancer primary prevention campaign in Australia be worthwhile?: an economic perspective. Health Promot Int 14 (1999), 73–82.
10. Scuffham, P.A., Tippett, V., The cost-effectiveness of thrombolysis administered by paramedics. Curr Med Res Opin 24 (2008), 2045–2058.
11. Segal, L., Day, S.E., Chapman, A.B., Osborne, R.H., Can we reduce disease burden from osteoarthritis?. Med J Aust 180:5 Suppl (2004), S11–S17.
12. Wong, G., Howard, K., Webster, A., et al. The health and economic impact of cervical cancer screening and human papillomavirus vaccination in kidney transplant recipients. Transplantation 87 (2009), 1078–1091.
13. Mauskopf, J.A., Cates, S.C., Griffin, A.D., et al. Cost effectiveness of zanamivir for the treatment of influenza in a high risk population in Australia. Pharmacoeconomics 17 (2000), 611–620.
14. Smith, M.G., Neville, A.M., Middleton, J.C., Clinical and economic benefits of ramipril: an Australian analysis of the HOPE study. Intern Med J 33 (2003), 414–419.
15. O'Leary, B.A., Olynyk, J.K., Neville, A.M., et al. Cost-effectiveness of colorectal cancer screening: comparison of community-based flexible sigmoidoscopy with fecal occult blood testing and colonoscopy. J Gastroenterol Hepatol 19 (2004), 38–47.
16. Eckermann, S.D., Martin, A.J., Stockler, M.R., et al. The benefits and costs of tamoxifen for breast cancer prevention. Aust NZJ Public Health 27 (2003), 34–40.
17. Ekert, H., Brewin, T., Boey, W., et al. Cost-utility analysis of recombinant factor Vila (NovoSeven) in six children with long-standing inhibitors to factor VIII or IX. Haemophilia 7 (2001), 279–285.
18. Butler, J.R., McIntyre, P., MacIntyre, C.R., et al. The cost-effectiveness of pneumococcal conjugate vaccination in Australia. Vaccine 22 (2004), 1138–1149.
19. Commonwealth Department of Health and Ageing, National Hospital Cost Data Collection. Cost report Round 12 (2007-2008). 2009, Commonwealth of Australia, Canberra.
20. Commonwealth Department of Health and Ageing, National Hospital Cost Data Collection. Public sector estimated cost weights, Round 12 (2007-2008), AR-DRG v5.1. 2009, Commonwealth of Australia, Canberra.
21. Finfer, S., Bellomo, R., Boyce, N., et al., Study Investigators, S.A.F.E., A comparison of albumin and saline for fluid resuscitation in the intensive care unit. N Engl J Med 350 (2004), 2247–2256.
22. Talmor, D., Greenberg, D., Howell, M.D., et al. The costs and cost-effectiveness of an integrated sepsis treatment protocol. Crit Care Med 36 (2008), 1168–1174.
23. Huang, D.T., Clermont, G., Dremsizov, T.T., Angus, D.C., ProCESS Investigators. Implementation of early goal-directed therapy for severe sepsis and septic shock: a decision analysis. Crit Care Med 35 (2007), 2090–2100.
24. Chen, H., Suda, K.J., Turpin, R.S., et al. High-versus low-dose fluconazole therapy for empiric treatment of suspected invasive candidiasis among high-risk patients in the intensive care unit: a cost-effectiveness analysis. Curr Med Res Opin 23 (2007), 1057–1065.
25. Golan, Y., Wolf, M.P., Pauker, S.G., et al. Empirical anti-candida therapy among selected patients in the intensive care unit: a cost-effectiveness analysis. Ann Intern Med 143 (2005), 857–869.
26. MacLaren, R., Sullivan, P.W., Cost-effectiveness of recombinant human erythropoietin for reducing red blood cells transfusions in critically ill patients. Value Health 8 (2005), 105–116.
27. Edwards, S.J., Campbell, H.E., Plumb, J.M., Cost-utility analysis comparing meropenem with imipenem plus cilastatin in the treatment of severe infections in intensive care. Eur J Health Econ 7 (2006), 72–78.
28. Peek, G.J., Mugford, M., Tiruvoipati, R., et al. CESAR trial collaboration. Efficacy and economic assessment of conventional ventilatory support versus extracorporeal membrane oxygenation for severe adult respiratory failure (CESAR): a multicentre randomised controlled trial. Lancet 374 (2009), 1351–1363.
29. Desai, A.A., Baras, J., Berk, B.B., et al. Management of acute kidney injury in the intensive care unit: a cost-effectiveness analysis of daily vs alternate-day hemodialysis. Arch Intern Med 168 (2008), 1761–1767.
30. American Thoracic Society, Understanding costs and cost-effectiveness in critical care — report from the Second American Thoracic Society Workshop in Outcomes Research. Am J Respir Crit Care Med 165 (2002), 540–550.
31. Medical Services Advisory Committee, Economics section of the MSAC guidelines. 2008, Commonwealth of Australia, Canberra.
32. Pharmaceutical Benefits Advisory Committee. Guidelines for preparing submissions to the Pharmaceutical Benefits Advisory Committee (version 4.3), 2008, Commonwealth of Australia, Canberra.
33. Study Investigators, N.I.C.E.-S.U.G.A.R., Finfer, S., Chittock, D.R., Su, S.Y., et al. Intensive versus conventional glucose control in critically ill patients. N Engl J Med 360 (2009), 1283–1297.
34. RENAL Study Investigators, Bellomo, R., Cass, A., Cole, L., et al. Intensity of continuous renal-replacement therapy in critically ill patients. N Engl J Med 361 (2009), 1627–1638.